Clinical trial
A Phase I/Randomized Phase II Trial of Idelalisib and Lenalidomide in Patients With Relapsed/Refractory Mantle Cell Lymphoma
This Phase I/II trial studies the safety and effectiveness of lenalidomide with or without idelalisib. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Idelalisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether lenalidomide is more effective with or without idelalisib in treating mantle cell lymphoma.
| Category | Value |
|---|---|
| Date last updated at source | 2017-05-03 |
| Study type(s) | Interventional |
| Expected enrolment | 106 |
| Study start date | 2013-07-01 |
| Estimated primary completion date | 2017-05-01 |